Exhibitors Search
ENCell Co., Ltd.
Booth no.
C60/H60
| Exhibition | PARTNERING |
|---|---|
| Country | Korea, South |
| Address | 201 Songpa-daero, Songpa-gu, Seoul, Republic of Korea |
| Tel (Rep.) | 02-6205-8050 |
| Website | http://www.encellinc.com/kr/ |
Company Introduction
ENCell Corp. is Korea’s leading CDMO specializing in advanced therapy medicinal products, particularly cell and gene therapy (CGT). Founded in 2018 and listed on KOSDAQ in 2024, it rapidly captured a 58% domestic market share. ENCell has partnered with 18 clients on 34 projects, contributing to 11 IND approvals. It uniquely offers GMP-certified facilities capable of simultaneous cell therapy and viral vector production, providing end-to-end integrated CDMO services including tailored process development, quality analysis, and manufacturing for clinical and commercial use, enabling cost-effective and high-quality CGT development without significant capital expenditure.
Promotional video
Exhibit Item
Early-passage allogeneic Wharton’s jelly-derived mesenchymal stem/stromal cells (EN001)
Exhibit Item Images
-
Product Name : Early-passage allogeneic Wharton’s jelly-derived mesenchymal stem/stromal cells (EN001)Early-passage Wharton’s jelly-derived mesenchymal stem cell therapy (EN001) is a high-quality, high-efficiency allogeneic MSC product manufactured through proprietary selection, isolation, and microenvironment-mimicking culture. Based on its excellent safety and efficacy in muscle and nerve disorders, it is currently under clinical trials in Korea
-
Product Name : Mesenchymal stem cell (MSC) or MSC-derived biologics for research and clinical usesBased on our high-quality mesenchymal stem cell therapeutic production capabilities, we can supply products for research or clinical trials. We can also supply mesenchymal stem cell-derived exosomes, proteins, and other materials.
Exhibit Description
Early-passage Wharton’s jelly-derived mesenchymal stem cell therapy (EN001) is a high-quality, high-efficiency allogeneic MSC product manufactured through proprietary selection, isolation, and microenvironment-mimicking culture. Based on its excellent safety and efficacy in muscle and nerve disorders, it is currently under clinical trials in Korea.
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.